Human CD19 Stable Cell Line - Hela

Name: Human CD19 Stable Cell Line - Hela
SKU: CSC-RO1110M
Availability: InStock

For research use only. Not intended for any clinical use.

Cat. No. : CSC-RO1110M

Host Cell : HeLa Size : >1x10⁶ frozen cells/vial

Inquire for Price

Cell Line Information

Cell Culture Information

Safety and Packaging

Gene Information

Cat. No.	CSC-RO1110M
Description	This cell line is engineered to stably overexpress human CD19.
Target Gene	CD19
Gene Species	Homo sapiens (Human)
Host Cell	HeLa
Host Cell Species	Homo sapiens (Human)
Applications	1. Studying the interactions between immune cells and cancer cells 2. Studying the mechanisms of resistance to immune checkpoint blockade 3. High-throughput screening 4. Drug target validation
Size	>1x10⁶ frozen cells/vial
Stability	Validated for at least 10 passages
Quality Control	Negative for bacteria, yeast, fungi and mycoplasma.
Storage	Liquid nitrogen
Shipping	Dry ice

Revival

Rapidly thaw cells in a 37°C water bath. Transfer contents into a tube containing pre-warmed media. Centrifuge cells and seed into a 25 cm2 flask containing pre-warmed media.

Mycoplasma	Negative
Format	One frozen vial containing millions of cells
Storage	Liquid nitrogen
Safety Considerations	The following safety precautions should be observed. 1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum. 2. No eating, drinking or smoking while handling the stable line. 3. Wash hands after handling the stable line and before leaving the lab. 4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells. 5. All waste should be considered hazardous. 6. Dispose of all liquid waste after each experiment and treat with bleach.
Ship	Dry ice

Gene Name	CD19 CD19 molecule [ Homo sapiens ]
Gene Symbol	CD19
Synonyms	CD19; CD19 molecule; CD19 antigen; B-lymphocyte antigen CD19; differentiation antigen CD19; T-cell surface antigen Leu-12; B-lymphocyte surface antigen B4; B4; CVID3; MGC12802;
Gene ID	930
Uni Prot ID	P15391
m RNA Refseq	BC006338
Chromosome Location	16p11.2
Function	receptor signaling protein activity;
Pathway	Adaptive Immune System, organism-specific biosystem; Antigen Activates B Cell Receptor Leading to Generation of Second Messengers, organism-specific biosystem; B Cell Receptor Signaling Pathway, organism-specific biosystem; B cell receptor signaling pathway, organism-specific biosystem; B cell receptor signaling pathway, conserved biosystem; BCR signaling pathway, organism-specific biosystem; Hematopoietic cell lineage, organism-specific biosystem;
MIM	107265

Quick Inquiry

Case Study

Q & A

Customer Reviews

Autologous T cells expressing CD19-specific chimeric antigen receptors (CARs) have been shown to have significant efficacy in the treatment of B-cell malignancies. Here, researchers constructed FLAG-tagged CD19-specific CAR-T cells (CD19-FLAG) and compared them with untagged CAR-T cells in vitro and in vivo experiments to understand their efficacy against solid tumors and hematological tumor cells. For solid tumors, the researchers used HeLa cervical carcinoma cells engineered to overexpress CD19 (HeLa-CD19); for hematological tumors, Raji Burkitt lymphoma cells that endogenously express CD19 were used. Like untagged CD19 CAR-T cells, CD19-FLAG CAR-T cells expanded more than 100-fold in in vitro culture and showed strong cytolytic activity against both HeLa-CD19 cells and Raji cells in vitro. CD19-FLAG CAR-T cells also secreted significantly more IFN-γ and IL-2 than control T cells. In vivo experiments, CD19-FLAG CAR-T cells significantly inhibited the growth of HeLa-CD19 solid tumors, increased the level of caspase-3 for tumor lysis, and achieved systemic expansion. CD19-FLAG CAR-T cells also significantly reduced Raji tumor burden and prolonged the survival of mice. These results demonstrate the powerful efficacy of FLAG-tagged CD19 CAR-T cells in solid tumor and blood tumor models.

Here, the researchers tested the ability of CD19 and CD19-FLAG CAR-T cells to kill CD19-bearing target cells using two human cell lines: Raji, a B-cell line that endogenously expresses CD19, and HeLa, a cervical cancer line that has been genetically engineered to overexpress CD19. Cytolysis was detected using the real-time cell analysis (RTCA) xCELLigence system, which measures the impedance of the target cell monolayer over time; as target cells are killed by effector cells, the impedance of the monolayer decreases. Both CD19 and CD19-FLAG CAR-T cells exhibited significant cytolytic activity against Raji cells (Figure 1A) and Hela-CD19 cells (Figure 1B), but not against HeLa cells (Figure 1C). In contrast, mock CAR-T cells and untransduced T cells showed no significant cytolytic activity against any target cells. Thus, both CD19 and CD19-FLAG CAR-T cells exhibited potent CD19-dependent cytolytic activity.

Figure 1. CD19-FLAG CAR-T cells are highly cytolytic for CD19+ cancer cells. (Berahovich R, et al., 2017)

Ask a Question

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.

Question *

Name

Country *

Email *

Write a Review

Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.

Product Name *

Catalog Name *

Rating

Needs improvement

Satisfaction

General satisfaction

Very satisfaction

Product Review Title *

Summary *